Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30100375

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Sep
First author
Kim YH

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Sep;19(9):1140-1141. doi: 10.1016/S1470-2045(18)30449-2.
    note
    Source null
    related pmid
    30100377
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Nov;19(11):e581. doi: 10.1016/S1470-2045(18)30772-1.
    note
    Source null
    related pmid
    30507485
    relationship
    Erratum in

Authors and identifiers

  1. name
    Kim YH
    type
    Author
  2. name
    Bagot M
    type
    Author
  3. name
    Pinter-Brown L
    type
    Author
  4. name
    Rook AH
    type
    Author
  5. name
    Porcu P
    type
    Author
  6. name
    Horwitz SM
    type
    Author
  7. name
    Whittaker S
    type
    Author
  8. name
    Tokura Y
    type
    Author
  9. name
    Vermeer M
    type
    Author
  10. name
    Zinzani PL
    type
    Author
  11. name
    Sokol L
    type
    Author
  12. name
    Morris S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kim YH
    type
    Author
  2. name
    Bagot M
    type
    Author
  3. name
    Pinter-Brown L
    type
    Author
  4. name
    Rook AH
    type
    Author
  5. name
    Porcu P
    type
    Author
  6. name
    Horwitz SM
    type
    Author
  7. name
    Whittaker S
    type
    Author
  8. name
    Tokura Y
    type
    Author
  9. name
    Vermeer M
    type
    Author
  10. name
    Zinzani PL
    type
    Author
  11. name
    Sokol L
    type
    Author
  12. name
    Morris S
    type
    Author
bibliography ids
  1. nci-bib-7793b51bf09efdcb886e55e2
book metadata
content sha256
9056cf35c79f2e655d054daeac9eb4d5a4e525a7a033f720a6cddc149db4b7ad
document type
citation
dois
  1. 10.1016/S1470-2045(18)30379-6
electronic publication date
display
2018 Aug 9
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30100375
immutable id
pubmed:30100375@9056cf35c79f2e655d054daeac9eb4d5a4e525a7a033f720a6cddc149db4b7ad
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
1192-1204
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Sep;19(9):1140-1141. doi: 10.1016/S1470-2045(18)30449-2.
    note
    Source null
    related pmid
    30100377
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Nov;19(11):e581. doi: 10.1016/S1470-2045(18)30772-1.
    note
    Source null
    related pmid
    30507485
    relationship
    Erratum in
outcomes validated
false
pmid
30100375
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
9911ebb509ba26895e21c8102ae3a1c65f9f3530e704aacc64bea1e25583bbb0
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Sep
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30100375/
title
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Preserved source evidence · Not medical advice